Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?

MLA

Hsin-Hua Chen, et al. “Is Drug Discontinuation Risk of Adalimumab Compared with Etanercept Affected by Concomitant Methotrexate Dose in Patients with Rheumatoid Arthritis?” Patient Preference & Adherence, vol. 10, Feb. 2016, pp. 123–34. EBSCOhost, https://doi.org/10.2147/PPA.S94396.

APA

Hsin-Hua Chen, Der-Yuan Chen, Yi-Ming Chen, & Chao-Hsiun Tang. (2016). Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis? Patient Preference & Adherence, 10, 123–134. https://doi.org/10.2147/PPA.S94396

Chicago

Hsin-Hua Chen, Der-Yuan Chen, Yi-Ming Chen, and Chao-Hsiun Tang. 2016. “Is Drug Discontinuation Risk of Adalimumab Compared with Etanercept Affected by Concomitant Methotrexate Dose in Patients with Rheumatoid Arthritis?” Patient Preference & Adherence 10 (February): 123–34. doi:10.2147/PPA.S94396.